Innovative translational research in leukemia is critically dependent on the availability of funding for pilotprojects. The Leukemia SPORE Developmental Research Program (DRP) will be a source of seed fundingwith the following goals: 1) encourage and explore innovative translational research ideas which focus onleukemia research; and 2) encourage successful researchers working in other fields to focus their expertisetoward the development of innovative translational projects in leukemia research. Both laboratory andclinical research projects are eligible for funding, provided that they are translational in nature. The purposeof the SPORE Developmental Research Program is to develop translational research projects that shouldresult in clinically-testable hypotheses aimed at improving prognosis for patients with leukemia. Support of$100,000 from the SPORE and $100,000 from matching institutional support as described in the letter ofInstitutional Commitment will provide a total of $200,000 per year available through the DevelopmentalResearch Program for approximately 4 to 5 projects (approximately $50,000 per project). Funding will beawarded for 1 year; with satisfactory review from the respective advisory committees and progress on theindividual projects' specific aims, the funding could be carried over for an additional year.The specific objectives of the Developmental Research Program are to:1. Publicize the availability of funds for pilot translational leukemia research studies. Identify throughthis mechanism innovative projects with significant potential for improving leukemia therapy andprognosis.2. Encourage collaborations of projects with scientists within the SPORE and outside the SPORE.3. Enhance the communication between the SPORE leaders and outside investigators to encouragethe development of innovative translational strategies in leukemia.4. Ensure program flexibility so that developmental projects that show promise can be: 1) funded fora second year; 2) encouraged to apply for peer-reviewed funding (i.e. R01); or 3) expanded tobecome full SPORE projects.Lay Description: Innovative translational research in leukemia is critically dependent on the availability offunding for pilot projects. The Leukemia SPORE Developmental Research Program will be a source of seedfunding with the following goals: 1) encourage and explore innovative translational research ideas whichfocus on leukemia research; and 2) encourage successful researchers working in other fields to focus theirexpertise toward the development of innovative translational projects in leukemia research

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100632-06
Application #
7468684
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2008-09-01
Budget End
2009-04-30
Support Year
6
Fiscal Year
2008
Total Cost
$92,643
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Fiorini, Elena; Santoni, Andrea; Colla, Simona (2018) Dysfunctional telomeres and hematological disorders. Differentiation 100:1-11
Cortes, Jorge; Perl, Alexander E; Döhner, Hartmut et al. (2018) Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 19:889-903
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Takahashi, Koichi; Wang, Feng; Morita, Kiyomi et al. (2018) Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9:2670
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Kayser, Sabine; Levis, Mark J (2018) Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol 180:484-500
Xia, Fang; Ning, Jing; Huang, Xuelin (2018) Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9:
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12

Showing the most recent 10 out of 487 publications